Notice Number: NOT-RM-08-001
Update: The following update relating to this announacement has been issued:
Release Date: October 12, 2007
Response Due By: October 31, 2007 (New Date March 15, 2008 per NOT-RM-08-003)
Since its inception, the NIH Roadmap for Medical Research http://nihroadmap.nih.gov/ has been an “incubator space” for initiatives that, due to their cross-cutting relevance and/or complexity, warrant concerted attention from NIH as a whole. Roadmap initiatives are designed to pursue major opportunities and gaps in research and to catalyze changes that will have a transforming effect on how biomedical and behavioral research is conducted over the next decade.
One of the major components of the overall Roadmap strategy is the Roadmap Epigenomics Program. http://nihroadmap.nih.gov/EPIGENOMICS/. The goals of the Roadmap Epigenomics Program are to establish multiple sets of comprehensive reference epigenomes; develop new reagents and tools for epigenetic research; provide publicly accessible data as well as new tools for data integration; and conduct research on novel hypotheses on epigenetic roles in human health and disease. Monoclonal antibodies against epigenetic targets will be valuable additions to the epigenetic toolbox.
Epigenetic Target Nomination
The Roadmap Epigenomics Program is now accepting nominations for targets for monoclonal antibodies that would be of use in epigenetics research. These targets/antigens could include 1. specific epigenetic marks (such as histone modifications or methyl cytosine), 2. proteins that generate, remove, or bind to epigenetic marks, 3. epigenetic effector molecules, or 4. other targets of significance to epigenetics researchers.
To nominate a target please follow the weblink http://www.drugabuse.gov/epigenomics/ and the instructions therein. You will be asked to provide information concerning:
NIH staff on the Epigenomics Working Group, with input from external scientific experts, will prioritize the nominations for the monoclonal antibody production queue.
Nominations must be submitted electronically through the following weblink: http://www.drugabuse.gov/epigenomics/. Responses will be accepted through October 31, 2007. Responses to any individual elements of the RFI are optional. The NIH site will permit anonymous responses. Responders should be aware that the information provided will be analyzed and may appear in various reports. Additionally, the government cannot guarantee the confidentiality of the information provided.
Specific questions about this RFI should be directed to the contacts listed below:
A. Roger Little Ph.D.
Senior Policy Advisor for Scientific Collaborations Office of Science Policy, Planning, and Communications
National Institute of Mental Health
6001 Executive Blvd, Room 8211, MSC 9667
Bethesda, Maryland USA 20892
Randall R. Stewart, Ph.D.
Program Director for Channels, Synapses and Circuits
National Institute of Neurological Disorders & Stroke
National Institutes of Health
6001 Executive Blvd., Room 2135
Bethesda, MD 20892-9523
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.